BCM
INZY

Bridgeway Capital Management’s Inozyme Pharma INZY Stock Holding History

Bridgeway Capital Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-105,800
Closed -$96.3K – 1209
2025
Q1 		$96.3K Buy
105,800
+29,600
+39% +$41K ﹤0.01% 1042
2024
Q4 		$211K Sell
76,200
-2,200
-3% -$8.37K ﹤0.01% 995
2024
Q3 		$410K Buy
+78,400
New +$407K 0.01% 909
2024
Q2 		– Sell
-17,800
Closed -$136K – 1304
2024
Q1 		$136K Sell
17,800
-34,000
-66% -$187K ﹤0.01% 1172
2023
Q4 		$221K Sell
51,800
-39,883
-44% -$142K ﹤0.01% 1115
2023
Q3 		$385K Sell
91,683
-24,917
-21% -$127K 0.01% 955
2023
Q2 		$649K Sell
116,600
-800
-0.7% -$4.73K 0.02% 841
2023
Q1 		$673K Sell
117,400
-16,000
-12% -$42.3K 0.02% 814
2022
Q4 		$140K Hold
133,400
– – ﹤0.01% 1163
2022
Q3 		$358K Buy
133,400
+46,000
+53% +$166K 0.01% 983
2022
Q2 		$417K Buy
87,400
+30,000
+52% +$130K 0.01% 925
2022
Q1 		$235K Sell
57,400
-20,000
-26% -$118K ﹤0.01% 1142
2021
Q4 		$528K Buy
+77,400
New +$669K 0.01% 969

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Bridgeway Capital Management's INZY Position: Q2 2025 in Review

Bridgeway Capital Management sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 105,800 shares — an estimated $96.3K sold.

Bridgeway Capital Management first reported a position in INZY in Q4 2021 and held it in 13 quarters. The position peaked at $673K in Q1 2023. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Bridgeway Capital Management reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 105,800 Inozyme Pharma shares in Q2 2025, an estimated $96.3K.
  • Bridgeway Capital Management first reported a position in Inozyme Pharma in Q4 2021 and held it in 13 quarters.
  • Bridgeway Capital Management's Inozyme Pharma position peaked at $673K in Q1 2023.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Bridgeway Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.